BIOMERICA INC
Biomerica develops, patents, manufactures and markets diagnostic and therapeutic products for patients and healthcare providers. Its diagnostic test kits analyze blood, urine, nasal or fecal samples to help diagnose diseases, food intolerances and other medical conditions. The company sells mainly to clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter channels. It also provides contract development and manufacturing services to third parties. Biomerica’s products include the inFoods® IBS blood test, which identifies foods associated with IBS symptoms, hp+detect™ for detecting H. pylori and monitoring treatment, and EZ Detect and Aware products. It makes money primarily through sales of diagnostic products, as well as contract development and manufacturing services. It is headquartered in Irvine, California, and also has manufacturing and assembly operations in Mexicali, Mexico, and a European subsidiary that supports sales and distribution.
No enriched coverage for $BMRA in the last 7 days.
No SEC Form 4 filings for $BMRA in the last 30 days.
See all $BMRA insider activity →Biomerica reported Q1 GAAP EPS of -$0.37 and revenue of $1.3M, down 7.1% year-over-year. The company had $2.7M in cash as of August 31, 2026, up from $1.3M in May 2026, according to its press release.
Biomerica (BMRA) reported a 120% increase in Medicare-related orders for its inFoods® IBS test in September 2026. The company processed all valid Medicare claims at a $300 rate. Operating expenses decreased 14% YoY, while OTC sales rose 81% QoQ. Cash reserves doubled to $2.7M. Net sales were $1.3M with an 8% gross margin, resulting in an operating loss of $1.2M.
Biomerica director David Moatazedi will not stand for re-election at the 2026 Annual Meeting on December 11, 2026. His decision is not due to any dispute with the company or board. Moatazedi has served on the board since December 2022.
Recent BMRA coverage spans earnings, insider activity and financial news.
Loss-making quarter with modest revenue decline and limited cash runway signals continued funding and execution risk.
Earnings miss and weak margins suggest short‑term downside pressure.
Board composition change with no immediate operational impact.
Board committee leadership will change ahead of the 2026 annual meeting, but the filing provides no operational or financial guidance impact.
The capital raise and improved quarterly results may support short‑term price upside.
AlphAI scores every news story that mentions BMRA with an AI model for sentiment and relevance, and aggregates insider trades from BIOMERICA INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Biomerica reported Q1 GAAP EPS of -$0.37 and revenue of $1.3M, down 7.1% year-over-year. The company had $2.7M in cash as of August 31, 2026, up from $1.3M in May 2026, according to its press release.
2 min readBiomerica (BMRA) reported a 120% increase in Medicare-related orders for its inFoods® IBS test in September 2026. The company processed all valid Medicare claims at a $300 rate. Operating expenses decreased 14% YoY, while OTC sales rose 81% QoQ. Cash reserves doubled to $2.7M. Net sales were $1.3M with an 8% gross margin, resulting in an operating loss of $1.2M.
2 min readBiomerica director David Moatazedi will not stand for re-election at the 2026 Annual Meeting on December 11, 2026. His decision is not due to any dispute with the company or board. Moatazedi has served on the board since December 2022.
1 min readBIOMERICA INC (BMRA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 12, 2026, David Moatazedi, a member of the Board of Directors (the “Board”) of Biomerica, Inc. (the “Company”),
2 min readBiomerica Inc. raised $2.23M in private placement funding. Q4 sales rose 17% to $875K, while net loss narrowed 27% to $1.5M. The company secured a $1.75M contract for diagnostic assay development and expanded into the Canadian market. Shares trade around $2.09 (Nasdaq: BMRA).
2 min readBIOMERICA INC (BMRA) reported FY 2026 revenue of $4.45M, down 16% YoY, and a net loss of $3.78M, improved from $4.97M in FY 2025. EPS was $(1.30), up from $(2.16). Revenue decline was due to lower clinical lab and OTC volumes. The company secured a CPT code and Medicare rate for inFoods® IBS and entered agreements targeting $1.75M in fees.
1 min readCarets Corp is exploring a potential sale, including its technology and patents. Algorhythm Holdings (RIME) and Biomerica (BMRA) are evaluating strategic alternatives. nVent Electric (NVT) acquired Maverick Power for $1.75B, with up to $550M more in performance-based payments. Descartes (DSGX) bought Tai for $100M, and Navitas (NVTS) acquired Claros for up to $232.8M. Booz Allen (BAH) completed a $720M acquisition, and Elastic (ESTC) acquired Deductive AI. BioXcel (BTAI) filed for Chapter 11 ban
3 min readGary M. Huff purchased 31,250 shares of BIOMERICA INC (BMRA) at $1.60 on 2026-08-20.
1 min readMOATAZEDI DAVID purchased 10,000 shares of BIOMERICA INC (BMRA) at $1.60 on 2026-08-26.
1 min readChin Eric purchased 6,250 shares of BIOMERICA INC (BMRA) at $1.60 on 2026-08-26.
1 min read
